Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is ...

The upcoming Supreme Court hearing on Braidwood Management v Becerra could affect how preventive services are covered by both ...

The clinical and financial implications of inpatient dermatology were examined, highlighting the need for systemic changes to ...

Increasing testing for both HIV and sexually transmitted infections (STIs) can help to mitigate the incidence of both in high ...

In part 3 of this conversation, Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance, discusses ...

While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol ...

Black individuals had a 2-fold risk of cancer death related to prostate, myeloma, and stomach cancers compared with White ...

The comparable rates of remission pre- and post-pandemic suggest that COVID-19 did not negatively impact the outcomes of ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing ...

Comparing plans with similar characteristics, such as size, geographic location, or demographics served, allows for more meaningful insights and improvement opportunities.